P. Vigeral

Low incidence of SARS-CoV-2, risk factors of mortality and the course of illness in the French national cohort of dialysis patients

E. M. Passos, L. Duflot, M. Brahimi, 2020, Kidney International.

Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent.

D. Droz, L. Chatenoud, J. Bach, 1986, Transplantation.

Nephrogenic diabetes insipidus and distal tubular acidosis in methicillin-induced interstitial nephritis.

F. Blanchet, A. Kanfer, P. Vigeral, 1987, Advances in experimental medicine and biology.

Therapeutic use of monoclonal antibodies in kidney transplantation.

L. Chatenoud, J. Bach, H. Kreis, 1991 .

Bartter's syndrome with normal chloride reabsorption during indomethacin treatment.

M. Kazatchkine, J. Bariéty, J. Truffert, 1987, Nephron.

Evaluation of Post-Puncture Bleeding Time of Arteriovenous Fistulas with IRIS® Bandage

M. Flamant, H. Boulanger, P. Vigeral, 2013, The journal of vascular access.

[Transient deafness in patients with renal insufficiency treated with erythromycin].

A. Kanfer, P. Vigeral, J. Méry, 1979, La Nouvelle presse medicale.

[Drug-induced renal insufficiency. Results of consensus meetings].

G. Danan, J. Grünfeld, G. Lagier, 1989, Nephrologie.